Pharmacovigilance
China’s new frontier: Seizing opportunities, overcoming obstacles

China’s expansive regulatory overhaul is expanding opportunities for pharma and biotech companies to launch clinical trials and fast-track new drug application approvals in this burgeoning global market.

**CHALLENGE:**
Navigating the complexities of language, culture, regulatory requirements and provincial policies presents a host of challenges that can delay or derail your program’s success. You need on-the-ground experts who understand the impact of new regulations on your specific program and who can quickly enact effective strategies for overcoming barriers along the way.

**SOLUTION:**
PPD’s China Pharmacovigilance team comprises experienced, local experts who tailor a solution that complies with both the Chinese regulatory requirements and with global PV-industry best practices. Our PV model incorporates efficient procedures, systems, and quality & compliance programs to help you effectively monitor and manage innovative therapy safety profiles during the clinical development phase and beyond.

**OUR EXPERIENCE**

- **6,000+** ICSRs submitted to the NMPA* for more than ten clinical studies
- **18+ years** of clinical development experience in China
- **80+** local and global clinical trials safety management in the past 5 years
- **5 years’** average experience in pharma and CROs across our China PV team

*National Medical Products Administration

China is the world’s second largest pharmaceutical market. Exhaustive regulatory reforms in China have paved the way for drug companies to expand their footprint in this vast and rapidly expanding global market. New regulations are designed to:

- Improve the drug review process through shortened IND and NDA review timelines to speed approvals
- Encourage new drug innovation
- Accelerate market authorization of medical innovations

HELPING DELIVER LIFE-CHANGING THERAPIES
**OUR CAPABILITIES**

- **Global and domestic ICSR processing**
  Safety specialists and medical directors who critically analyze safety data in Mandarin, English and Japanese

- **Local literature surveillance**
  Search strategies for English and Chinese scientific literature databases including CNKI, Wanfang Data and VIP
  Abstract review, article procurement and assessment in English and Mandarin

- **Safety Reporting**
  E2B submission to the NMPA
  Paper submission to the National Health Commission (NHC)
  Portal submission of post-approval Adverse Drug Reaction (ADR) to the National Centre for ADR Monitoring

- **Safety Writing**
  Chinese Development Safety Update Report (DSUR)
  Chinese Periodic Safety Update Report (C-PSUR)
  Chinese Marketing Automation Holder (MAH) Annual Summary Report

- **Pharmacovigilance Consulting**
  Safety database build, E2B submission module set-up
  PV audit/inspection readiness
  SOP development

- **China- Shanghai/ Beijing**
  **Leo Yu** - Associate Director, PVG
  Email: Leo.Yu@ppd.com
  Phone: +86 021 33072197 | Mobile: +86 13761812875
  Address: Unit 1101, Henderson Metropolitan, No. 155 Tianjin Road, Huangpu District, Shanghai 200001

- **China- Shenyang**
  **Richard Gang** - Manager, PVG
  Email: richard.gang@ppd.com
  Phone: +86 024 31054637 | Mobile: +86 13514206172
  Address: Unit 4301-4307, Fortune Plaza, Tower A No. 61 Beizhan Road, Shenhe District, Shenyang, 110013

**OUR SOLUTIONS**

- Full PV global capabilities with extensive knowledge of China’s evolving PV regulations
- Deep experience in Oracle’s Argus Safety and ArisGlobal’s LifeSphere Safety MultiVigilance (formerly ARISg) safety databases, including implementation and management of ARISc (Chinese-language safety database)
- Integrated global drug safety system that is designed to capture China-specific data elements and safety reporting requirements defined by the Centre for Drug Evaluation (CDE) and the National Medical Products Administration (NMPA)
- Local safety specialists and medical directors, fluent in English and Mandarin, who review safety data in both languages and effectively communicate with the NMPA, local, and global customers
- PV teams based in Shanghai, Beijing and Shenyang provide business continuity, flexible pricing and potential cost savings
- Adherence in China to the same stringent global SOPs, procedures and quality standards as other countries

**CONTACT INFORMATION**

Contact us at +1 877 643 8773 | +1 919 456 5600
ppdinfo@ppd.com
© 2021 PPD, Inc. All Rights Reserved. 03.2021